20
What are the latest advances in Essential Thrombocythemia?
Here you can see the latest advances and discoveries made regarding Essential Thrombocythemia.
The new World Health Organization (WHO) diagnostic criteria for essential thrombocythemia (ET) issued in 2008 made an important distinction between true ET and early myelofibrosis (MF), which has helped to identify a more homogenous population for the diagnosis with longer survival and much less transformation to overt MF. The recent finding of a new mutation (CALR), which is mutually exclusive with JAK2 and MPL mutations, adds to the characterization of ET patients, since there are important phenotypic differences between the mutation types. CALR patients are younger, have lower white blood cell counts (WBC) and a lower thrombosis incidence. A growing field of interest is the state of hypercoagulation due to dysfunction of hemostatic systems, cell–cell interaction and hereditary prothrombotic traits.
UNIVERSITY of York scientist has been granted £1.2m in new funding from Cancer Research UK to carry out research for six years into a specific kind of blood cancer.
Latest research news....10th August 2017.....Great news!!
Dr Ian Hitchcock, lecturer in biomedical sciences in York’s department of biology, will investigate myeloproliferative neoplasms (MPNs) - a group of blood cancers that cause the over-production of red blood cells and platelets.
There are over 3,000 new MPN cases diagnosed in the UK each year and the majority of these occur in older people.
nfortunately, current treatments for MPNs focus more on reducing patients’ symptoms rather than treating the disease itself.
Dr Hitchcock said: “There are a limited number of curative treatment options available to people with MPNs.
“With this funding from Cancer Research UK we hope to change this.
"We will use truly groundbreaking technologies to answer questions about MPNs which previously would have been impossible and use these answers to develop new, targeted treatments.
“This award is critical for our research at York. It will allow us to make key new findings in the field of blood cancers and hopefully help patients lead better lives and survive longer. It’s very exciting and I can’t wait to get going.”
UNIVERSITY of York scientist has been granted £1.2m in new funding from Cancer Research UK to carry out research for six years into a specific kind of blood cancer.
Latest research news....10th August 2017.....Great news!!
Dr Ian Hitchcock, lecturer in biomedical sciences in York’s department of biology, will investigate myeloproliferative neoplasms (MPNs) - a group of blood cancers that cause the over-production of red blood cells and platelets.
There are over 3,000 new MPN cases diagnosed in the UK each year and the majority of these occur in older people.
nfortunately, current treatments for MPNs focus more on reducing patients’ symptoms rather than treating the disease itself.
Dr Hitchcock said: “There are a limited number of curative treatment options available to people with MPNs.
“With this funding from Cancer Research UK we hope to change this.
"We will use truly groundbreaking technologies to answer questions about MPNs which previously would have been impossible and use these answers to develop new, targeted treatments.
“This award is critical for our research at York. It will allow us to make key new findings in the field of blood cancers and hopefully help patients lead better lives and survive longer. It’s very exciting and I can’t wait to get going.”
Posted Aug 11, 2017 by Steve 2685
i know they are discovering new drugs and treatments every day!!!
Posted Feb 7, 2019 by James 3550
